Medicare issues final decision covering certain CAR T-cell therapies

Medicare will cover nationally Chimeric Antigen Receptor T-cell therapies approved by the Food and Drug Administration to treat certain cancers, as well as off-label uses recommended by compendia approved by the Centers for Medicare & Medicaid Services, the agency announced yesterday. The therapies, which use a patient’s own genetically modified immune cells to fight cancer, must be administered at health care facilities enrolled in FDA’s risk evaluation and mitigation strategies. Currently, the FDA has approved CAR T-cell therapy for certain types of leukemia and non-Hodgkin lymphoma. The policy also continues coverage for routine costs in certain clinical trials that use CAR T-cell therapy.
Related News Articles
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…
Headline
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers…
Headline
A study published June 25 by the Journal of the American Heart Association found that heart disease death rates fell 66% from 1970 to 2022. Deaths from heart…
Headline
A report released June 17 by NORC at the University of Chicago, commissioned by the Coalition to Strengthen America’s Healthcare, found that patients enrolled…
Headline
The Centers for Medicare and Medicaid Services May 30 released a notice requesting comments on a proposed Medicare Advantage service level data collection…